Vectura Group plc UK court ruling in GSK v Sandoz passing off case
04 Ottobre 2019 - 2:14PM
RNS Non-Regulatory
TIDMVEC
Vectura Group plc
04 October 2019
UK court dismisses GSK's claims of passing off in respect of
Sandoz's AirFluSal(R) Forspiro(R)
Chippenham, UK - 4 October 2019: Vectura Group plc (LSE: VEC)
("Vectura" or "the Group") announces that the English High Court*
has dismissed all of GSK's claims of passing off in respect of
Sandoz's AirFluSal(R) Forspiro(R).
This action is one of a number of actions brought throughout
Europe by GSK against Sandoz, directed towards the sale and
distribution by Sandoz of AirFluSal(R) Forspiro(R), none of which
to date have been ultimately been successful.
Forspiro(R) is a proprietary dry powder inhaler developed by
Vectura and licensed to Sandoz for use with the AirFluSal(R)
product.
*Glaxo Wellcome UK Limited & Another v Sandoz Limited &
Others [2019] EWHC 2545 (Ch)
- Ends-
For more information, please contact:
Vectura Group plc
David Ginivan - VP Corporate Communications +44 (0)7471 352 720
Elizabeth Knowles - VP Investor Relations +44 (0)7767 160 565
Consilium Strategic Communications
Mary-Jane Elliott / Sue Stuart / David Daley +44 (0)20 3709 5700
Background:
Seretide(R) is a combination of two active ingredients which act
in different ways to make it easier to breathe: fluticasone (an
anti-inflammatory steroid medicine that reduces inflammation and
mucus secretion in the lungs) and salmeterol (a long-acting
bronchodilator that relaxes the muscles in the lungs). Seretide(R)
is sold by GSK in the UK in two product forms: a disc inhaler sold
under the brand name Seretide(R) Accuhaler(R) and a metered dose
inhaler, sold under the brand names Seretide(R) and Evolhaler(R).
Both the GSK products are coloured two shades of purple.
On 20(th) November 2015 Sandoz launched a branded generic
competitor to Seretide(R) Accuhaler(R) under the trademark
AirFluSal Forspiro(R). Forspiro(R) is a proprietary dry powder
inhaler developed by Vectura. AirFluSal Fospiro(R) is largely
coloured a shade of purple and is sold in packaging featuring a
shade of purple.
GSK launched a legal action which claimed that Sandoz passed off
AirFluSal Forspiro(R) as being connected in the course of trade
with GSK and/or as being equivalent to Seretide(R) Accuhaler(R)
through its get up and packaging. Vectura were joined to the action
during the course of proceedings and are indemnified by Sandoz.
About Vectura
Vectura is a provider of innovative inhaled drug delivery
solutions that enable partners to bring their medicines to
patients. With differentiated proprietary technology and
pharmaceutical development expertise, Vectura is one of the few
companies globally with the device, formulation and development
capabilities to deliver a broad range of complex inhaled
therapies.
Vectura has ten key inhaled and eleven non-inhaled products
marketed by partners with global royalty streams, and a diverse
partnered portfolio of drugs in clinical development. Our partners
include Hikma, Novartis, Sandoz (a division of Novartis AG),
Mundipharma, Kyorin, GSK, Bayer, Chiesi, Almirall, and Tianjin
KingYork.
For further information, please visit Vectura's website at
www.vectura.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAFZLFBKBFEFBE
(END) Dow Jones Newswires
October 04, 2019 08:14 ET (12:14 GMT)
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Vectura (LSE:VEC)
Storico
Da Apr 2023 a Apr 2024